A recent study indicated that severe COVID-19 patients displayed dysregulated expression of checkpoint molecules PD-1 and its ligand PD-L1, indicating that these checkpoint molecules could be considered as prognostic markers and therapeutic targets for COVID-19 [38,39]. The gene discussed is CD274; the disease is COVID-19.